AI assistant
Skye Bioscience, Inc. — Director's Dealing 2024
Nov 20, 2024
34097_dirs_2024-11-19_5f150ab4-31ae-479a-b64b-6fac286a260f.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Skye Bioscience, Inc. (SKYE)
CIK: 0001516551
Period of Report: 2024-11-15
Reporting Person: DHILLON PUNIT (Director, Chief Executive Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2024-11-15 | Common Stock | S | 364 | $5.55 | Disposed | 412369 | Direct |
| 2024-11-18 | Common Stock | S | 82546 | $4.99 | Disposed | 329823 | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 9343 | Indirect |
Footnotes
F1: The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of performance-based restricted stock units. The sales were to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary transactions by the Reporting Person.
F2: The price reported is a weighted average price. These shares were sold as part of a block trade in multiple transactions at prices ranging from $4.98 to $5.08, inclusive. The Reporting Person will provide to the staff of the Securities and Exchange Commission, the issuer, or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price with regard to the block trade.
F3: Shares held by a family trust of which the reporting person is the trustee.